Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy

Niels Fisker, Majken Westergaard, Henrik Frydenlund Hansen, Jens Bo Hansen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

We have investigated the effects of different locked nucleic acid modified antisense mRNA antagonists against Survivin in a prostate cancer model. These mRNA antagonists were found to be potent inhibitors of Survivin expression at low nanomolar concentrations. Additionally there was a pronounced synergistic effect when combining the mRNA antagonists against Survivin with the chemotherapeutic Taxol. This effect was demonstrated at concentrations of antagonists far lower than any previously demonstrated, indicating the high potential of locked nucleic acid for therapeutic use. Further characterisations in vivo are ongoing.

OriginalsprogEngelsk
TidsskriftNucleosides, Nucleotides and Nucleic Acids
Vol/bind26
Udgave nummer10-12
Sider (fra-til)1427-1430
ISSN1525-7770
DOI
StatusUdgivet - 2007
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy'. Sammen danner de et unikt fingeraftryk.

Citationsformater